THE VACCINE MAKER MODERNA decided this past week to tell the world about bad news it had received from the federal government ...

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over ...

Moderna is a well-known biotech company from its pandemic success. Here's what investors should know about its growth story now.

Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.